Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Journey Medical Q1 2026 Earnings Call - EMROSI Revenues Jump 21% as Reimbursement Wins Fuel Operating Leverage
Journey Medical delivered a strong first quarter with total revenues reaching $16 million, driven by a 200% year-over-year surge in EMROSI sales to $6.3 million. The company reported its third consecu...
- EMROSI revenues surged 200% year-over-year to $6.3 million, contributing to total net product revenue growth of 21% to $16 million.
- The company achieved positive adjusted EBITDA of $600,000 for the third consecutive quarter, reflecting improving operating leverage.
- Cash reserves increased to $27.2 million by quarter end, up from $24.1 million in December 2025.
- +7 more takeaways
Aytu Biopharma Q3 FY2026 Earnings Call - EXXUA Launch Accelerates With 26% Monthly Script Growth
Aytu Biopharma's first full commercial quarter for EXXUA, its novel antidepressant, delivered a 26% month-over-month script growth rate, climbing from 200 prescriptions in January to over 900 in April...
- EXXUA script volume surged 26% month-over-month in April, reaching over 920 prescriptions, up from 700 in March, signaling accelerating physician adoption.
- More than 1,300 prescriptions were written in Q3 by over 450 unique prescribers, representing 10-13% of the initial 3,500-4,000 targeted physician universe.
- EXXUA generated $2.4 million in net revenue for Q3, exceeding management's initial launch expectations and demonstrating strong early commercial traction.
- +7 more takeaways
Usio Q1 FY2026 Earnings Call - Record Revenue Growth Driven by PayFac and Real-Time Payments Momentum
Usio delivered a record first quarter for fiscal 2026, posting 16% year-over-year revenue growth to reach an all-time high. The company achieved positive GAAP net income, adjusted EBITDA, and operatin...
- Usio reported record quarterly revenue of $38.5 million (implied by 16% growth context), representing a 16% year-over-year increase and a new all-time high for the company.
- The company achieved positive GAAP net income of approximately $130,000, along with positive adjusted EBITDA and operating cash flow, signaling a successful transition to sustainable profitability.
- Card processing revenue surged 23% year-over-year to $9.7 million, driven primarily by the PayFac segment which now constitutes 78% of card revenues and is growing at a rate exceeding 20%.
- +9 more takeaways
Longeveron Q1 2026 Earnings Call - FDA Drops Pivotal Status for HLHS Trial, Shifts to Asset-Light Partnership Model
Longeveron is pivoting to an asset-light, partnership-driven strategy as it prepares for a critical regulatory juncture. The FDA has withdrawn pivotal status from the ELPIS II trial for laromestrocel ...
- CEO Stephen Willard completed a strategic review in February, transitioning Longeveron to an asset-light model focused on licensing partnerships for laromestrocel across all four development programs.
- The FDA withdrew pivotal status from the ELPIS II trial in hypoplastic left heart syndrome (HLHS), rejecting right ventricle ejection fraction (RVEF) as a valid primary efficacy endpoint.
- Management plans to submit a revised statistical analysis plan (SAP) to the FDA post-August 2026 data readout, focusing on composite endpoints like all-cause mortality and cardiac transplant-free survival.
- +7 more takeaways
Precigen Q1 2026 Earnings Call - PAPZIMEOS Revenue Surges 535% on Rapid Commercial Uptake
Precigen delivered a striking first quarter for its newly approved RRP therapy, PAPZIMEOS, with net product revenue jumping to $21.6 million from $3.4 million in the prior quarter. The acceleration re...
- PAPZIMEOS net product revenue surged 535% quarter-over-quarter to $21.6 million in Q1 2026, up from $3.4 million in Q4 2025.
- Total revenue reached $23.3 million, driven by strong commercial uptake of the newly approved RRP therapy.
- Operating loss improved to $6 million, with R&D expenses declining $4.8 million year-over-year as manufacturing costs are no longer expensed pre-approval.
- +11 more takeaways
MDxHealth Q1 2026 Earnings Call - Exiting Resolve UTI Business to Double Down on Prostate Cancer Diagnostics
MDxHealth is pulling the plug on its Resolve UTI test and closing its Plano, Texas lab to eliminate reimbursement uncertainty and refocus entirely on its prostate cancer precision diagnostics. The mov...
- MDxHealth is discontinuing its Resolve UTI test and closing its Plano, Texas laboratory to eliminate exposure to reimbursement uncertainty, particularly after Texas Medicare administrator Novitas Solutions reversed policy and sought $10.4 million in historical claim recoupments.
- Q1 2026 core prostate cancer revenue grew 11% year-over-year to $23.9 million on a pro forma basis, excluding the Resolve business entirely from the calculation.
- Pro forma gross margin for the quarter was 62.9%, down from 68% in Q1 2025, a decline management attributes to a shift in the mix between tissue-based and liquid-based testing.
- +7 more takeaways
Rapid Micro Biosystems Q1 2026 Earnings Call - Recurring Revenue Surges as Samsung Deal Drives Placements
Rapid Micro Biosystems delivered an 11% year-over-year revenue increase to $8 million in Q1 2026, fueled by a record 36% jump in product revenue and a 28% rise in recurring revenue, which now accounts...
- Total revenue grew 11% year-over-year to $8 million, driven by strong momentum in both system placements and recurring revenue streams.
- Product revenue surged 36% to $5.6 million, led by a record consumables quarter with over 30% growth as installed base utilization increased.
- Recurring revenue climbed 28% to $5.1 million, now representing 63% of total revenue and highlighting the shift toward a more predictable, service-heavy business model.
- +7 more takeaways
Inovio Pharmaceuticals Q1 2026 Earnings Call - FDA Review Proceeds Amidst Accelerated Approval Debate and Cash Runway Extended
Inovio Pharmaceuticals reported a streamlined first quarter with operating expenses down 13% as the company burns cash to advance its lead candidate, INO-3107, toward a PDUFA date of October 30, 2026....
- INO-3107 BLA review progresses with FDA completing mid-cycle review without raising new significant issues, setting stage for late-cycle review in Q3 2026.
- FDA has agreed to an informal meeting to discuss INO-3107's eligibility for accelerated approval, a critical regulatory hurdle for the October 30, 2026 PDUFA date.
- Inovio raised $16 million in an April 2026 public equity offering, strengthening its balance sheet and extending cash runway into Q1 2027.
- +7 more takeaways
Lightwave Logic Q1 2026 Earnings Call - Market Expansion and Silicon Photonics Integration
Lightwave Logic reported a 27% year-over-year revenue increase to approximately $29,000 for Q1 2026, while maintaining a strong cash position of $100 million after utilizing its existing shelf registr...
- Revenue for Q1 2026 reached approximately $29,000, marking a 27% year-over-year increase.
- Net loss for the quarter was $6.3 million, or $0.04 per share, compared to a net loss of $4.7 million in the prior year period.
- Cash on hand increased to approximately $100 million as of May 11, 2026, after utilizing existing shelf registrations.
- +12 more takeaways
Seer Q1 2026 Earnings Call - Revenue Misses Amid Academic Funding Slump, But Biobank Momentum and IP Defense Signal Long-Term Play
Seer reported a sharp Q1 2026 revenue decline to $2.8 million, driven by a prolonged slump in academic and government funding, lumpy service project timing, and increased competition from lower-priced...
- Q1 2026 total revenue fell 33% year-over-year to $2.8 million, missing expectations due to depressed academic funding, competitive pressure from inferior imitators, and a lumpy service pipeline that lacked a major Q1 project.
- Management reaffirmed full-year 2026 revenue guidance of $16 million to $18 million, projecting approximately 3% growth at the midpoint over 2025, citing a 9-to-12-month lag in consumable reorders from last year's strong instrument install base.
- Operating expenses were aggressively cut to $18.2 million, a $4.6 million year-over-year reduction, driven by lower employee compensation and professional services costs, demonstrating strict capital discipline despite the revenue headwinds.
- +7 more takeaways